Intravesical Instillation of Mitomycin-C in 242 Patients with Superficial Bladder Cancer at High Risk of Recurrence: Long-Term Results

1998 ◽  
Vol 61 (4) ◽  
pp. 220-226 ◽  
Author(s):  
R. Hurle ◽  
A. Manzetti ◽  
A. Losa ◽  
E. Micheli ◽  
A. Ranieri ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
High Risk ◽  
Mitomycin C ◽  
Superficial Bladder Cancer ◽  
Intravesical Instillation ◽  
Long Term Results ◽  
Risk Of Recurrence

277: Long Term Follow Up of a Randomised Study of BCG Versus Mitomycin-C in High Risk Superficial Bladder Cancer

2004 ◽  
Vol 171 (4S) ◽  
pp. 73-73 ◽  
Author(s):  
Truls Gårdmark ◽  
Per-Uno Malmstrom ◽  
Peter Wiklund ◽  
Staffan Jahnson ◽  
Hans Wijkström ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
High Risk ◽  
Mitomycin C ◽  
Superficial Bladder Cancer ◽  
Randomised Study ◽  
Long Term Follow Up

832: Optimized Intravesical Mitomycin C Treatment for Superficial Bladder Cancer: Long-Term Follow-Up

2006 ◽  
Vol 175 (4S) ◽  
pp. 268-269 ◽  
Author(s):  
Jessie L. Au ◽  
Robert A. Badalament ◽  
M. Guillaume Wientjes ◽  
Donn C. Young ◽  
Tong Shen ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Mitomycin C ◽  
Superficial Bladder Cancer ◽  
Long Term Follow Up

Long-term results of organ preservation rate and progression risk in high-risk non-muscle-invasive bladder cancer (NMIBC) patients treated with radiofrequency-induced thermochemotherapy effect (RITE) with the Synergo system.

2018 ◽  
Vol 36 (6_suppl) ◽  
pp. 456-456
Author(s):  
Jill-Isabel Kilb ◽  
Arne Hauptmann ◽  
Florian Wagenlehner ◽  
Gerson Luedecke
Keyword(s):  
High Risk ◽  
Mitomycin C ◽  
Organ Preservation ◽  
Low Risk ◽  
Long Term Results ◽  
Induction Phase ◽  
Minimal Risk ◽  
Bladder Preservation ◽  
Preservation Rate

456 Background: High risk NMIBC is a dangerous BC with a challenging treatment by BCG or early cystectomy to cure. The first has bad treatment tolerance and a remission of about 35%, whereas the last offer a curing perspective of 84% with extremely bad living conditions. RITE checked prospectively the therapy in respect to organ preservation, curing rate and risk of progression over 10 years in a single institution experience. Methods: All patients were EORTC high risk NMIBC. Treatment with induction phase: 8 treatments weekly with 2x40 mg Mitomycin C, 42°C intravesically induced by RITE. Followed by a re-resection of the bladder at week 11 to ensure complete remission and maintenance with treatments every 6 weeks with 2x20 mg Mitomycin C for 6 times. Cystoscopy controls were performed first 2 years every 3 month and following in 6 month until now. Study started in 2006 ongoing until today. Results: We enrolled 67 patients (4 female, 63 male), 65.7% Cis positive rate. 85% of the patients were treated alternatively to BCG with primary RITE whereas 15% were BCG failure patients treated alternatively to indicated cystectomy. Tumor persistence at week 11 after induction therapy proven by TURB was (10/67) 14.9% resulting in early cystectomy (4/10). Mean recurrence free time 3.5 years. In case of recurrence 10.4% progressed to MIBC including 6% metastatic tumors, high risk NMIBC was observed in 6% resulting in cystectomy and low risk NMIBC recurrence was 1.5% with organ preservation. BC death rate was 1 out of 67. Incomplete treatments induced by SAE of RITE was 9%. Bladder preservation rate was 80.6% with a long-lasting effectiveness ( > 5 years) of 14/26 (53.8%). Conclusions: The RITE method is in short- and long-term manner a powerful procedure to cure and maintain a recurrence free BC status in high risk NMIBC with a very low risk for cystectomy and a minimal risk for systemic progression resulting in BC death. The organ preservation rate was achieved in 80.6% lasting for up to 11 years longest. RITE is an alternative to BCG and preferable to early cystectomy in high risk NMIBC.

scholarly journals Analysis of Japanese Patients Treated with or without Long-Term Epirubicin Plus Ara-C Intravesical Instillation Therapy for Low-Grade Superficial Bladder Cancer

2015 ◽  
Vol 2015 ◽  
pp. 1-5 ◽  
Author(s):  
Tomonori Kato ◽  
Kazushi Nomura ◽  
Fukuo Kondo ◽  
Masami Wakisaka ◽  
Akira Komiya
Keyword(s):  
Bladder Cancer ◽  
Tumor Recurrence ◽  
Superficial Bladder Cancer ◽  
Transitional Cell ◽  
Japanese Patients ◽  
Intravesical Instillation ◽  
Intravesical Chemotherapy ◽  
Low Grade ◽  
Free Rate

The high incidence of tumor recurrence following transurethral resection (TUR) represents a major problem encountered in the management of bladder cancer. This study examined the efficacy of intravesical chemotherapy in superficial bladder cancer. We retrospectively analyzed 90 Japanese cases with low-grade superficial transitional cell carcinoma (stage T1, grades 1 and 2) who were rendered tumor-free by TURBT (TUR of bladder tumor) and who thereafter were treated with or without intravesical chemotherapy. Among them, instillation was terminated in 2 patients due to adverse effects (severe but reversible chemical cystitis). Remaining 88 patients were divided into 2 groups according to therapy: the TURBT-only group(n=46), defined as patients treated with TURBT alone, and the Instillation group(n=42), defined as patients treated with weekly intravesical instillation therapies using epirubicin plus Ara-C. Recurrence-free rate was significantly higher in the Instillation group than in the TURBT-only group (p=0.02, HR = 0.457). The 5-year recurrence-free rate was 58.5% for the Instillation group and 38.6% for the TURBT-only group. Our instillation schedule represents the most intensive regimen among previously reported therapies and resulted in a 54.3% decrease in incidence of tumor recurrence. We believe that the results of this study could provide useful information on management of bladder cancer.

Sign in / Sign up

Export Citation Format

Share Document